These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8744654)

  • 21. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 23. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
    O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
    Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns.
    Grieb P; Kamienowski J; Janisz M; Kuśnierczyk P; Kawiak J; Hoser G; Chrapusta SJ
    Int J Hematol; 2001 Dec; 74(4):421-7. PubMed ID: 11794698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 26. Histological examination of the retinal ganglion layer in rabbits after experimental administration of the new immunosuppressive medicine--Cladribine.
    Kwietniewska M; Cybulska R; Kwietniewski P; Sekita-Krzak J; Czerny K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):376-80. PubMed ID: 12898865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
    Laugel B; Borlat F; Galibert L; Vicari A; Weissert R; Chvatchko Y; Bruniquel D
    J Neuroimmunol; 2011 Dec; 240-241():52-7. PubMed ID: 22035961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
    Grieb P; Stelmasiak Z
    Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
    Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
    Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
    Robak T; Góra-Tybor J
    Neoplasma; 2001; 48(3):203-7. PubMed ID: 11583290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N; Filippi M; Hawkins C;
    J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological examination of the lacrimal gland after experimental administration of Cladribine.
    Kwietniewska M; Czerny K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):526-30. PubMed ID: 12898890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
    Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
    Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
    Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
    Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cladribine: limited evaluation in multiple sclerosis.
    Prescrire Int; 2011; 20(118):175. PubMed ID: 21751748
    [No Abstract]   [Full Text] [Related]  

  • 39. [A plan for risk management in the treatment of multiple sclerosis with movectro (cladribine tablets)].
    Khachanova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):99-104. PubMed ID: 21916164
    [No Abstract]   [Full Text] [Related]  

  • 40. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
    Gummi R; Walsh RD; Ahmad B
    Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.